WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced that the Company has appointed James J. O’Leary, MD, as Vice President and Chief Medical Officer. Dr. O’Leary will lead the clinical development of ImmunoGen’s product candidates.
